Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation during the...

Descripción completa

Detalles Bibliográficos
Autores principales: Suliman, Aasir M., Bek, Shaza A., Elkhatim, Mohamed S., Husain, Ahmed A., Mismar, Ahmad Y., Eldean, M. Z. Sharaf, Lengyel, Zsolt, Elazzazy, Shereen, Rasul, Kakil I., Omar, Nabil E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979647/
https://www.ncbi.nlm.nih.gov/pubmed/33070259
http://dx.doi.org/10.1007/s00262-020-02726-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979647/
https://www.ncbi.nlm.nih.gov/pubmed/33070259
http://dx.doi.org/10.1007/s00262-020-02726-1

Ejemplares similares